Should You Buy Aurora Cannabis (TSX:ACB) After its 1st-Quarter Performance?

Despite lower-than-anticipated sales, I expect Aurora Cannabis’s financials to improve in the coming years and could deliver superior returns over the next three years.

| More on:
edit Jars of marijuana

Image source: Getty Images

Yesterday, Aurora Cannabis (TSX:ACB)(NYSE:ACB) reported its first-quarter earnings, which ended on September 30. Its revenue of $60.1 million fell below analysts’ expectations of $61.33 million. However, its adjusted EBITDA losses came in at $12.1 million better than analysts’ expectation of a loss of $14.4 million. Amid weak sales numbers, the company was trading over 2.5% lower in the after-market hours yesterday. So, let’s look at Aurora Cannabis’s first-quarter performance in more detail to assess whether it would make a good buy right now.

Aurora Cannabis’s first-quarter performance

Year over year, Aurora Cannabis’s revenue declined by over 11% amid weak performance from its recreational cannabis segment, which witnessed a 44% decline in its sales. The company’s management has blamed reduced orders from the Canadian provinces amid the pandemic for the sales decline. Meanwhile, its medical sales rose in both domestic and international markets, offsetting some of the declines.

Its adjusted gross margin improved from 48% to 54% on the back of increased sales contribution from higher-margin medical cannabis sales and a favourable sales mix amid a shift towards premium products. Also, the company’s adjusted EBITDA losses contracted from $58.1 million to $12.1 million. Higher gross margins and cost-reduction initiatives under the business transformation plan helped lower its adjusted EBITDA losses.

With Aurora Cannabis focusing on improving its operational efficiency and effective utilization of its assets, its operating cash flows have improved, thus lowering the need for additional capital. Its net cash burn fell from $142.8 million in the corresponding quarter of the previous year to $16.55 million. Besides, the company closed the quarter with its cash and cash equivalent standing at $424.3 million. So, the company’s financial position looks healthy.

Aurora Cannabis’s growth prospects

Amid increased legalization and rising usage of cannabis for medical purposes, the cannabis market is growing. Currently, only 1% of the Canadian population uses cannabis to treat their ailments. So, there is significant scope for growth in the medical cannabis segment.

Meanwhile, Aurora Cannabis is a leader in the Canadian medical cannabis space by acquiring 23% of the market share.  With its medical cannabis segment delivering over 60% of gross margins, the company has allocated more resources to the segment to drive growth. It is focusing on educating patients while also navigating them through alternative treatments, which could boost its financials. Additionally, the company looks to increase its international sales by strengthening its position in Israel, the U.K., Australia, and France.

With price being a primary driver in the discount segment, Aurora Cannabis expects the segment to create issues in the future. So, it plans to focus only on the premium and high THC-content products in the Canadian recreational cannabis market. Overall, the company’s growth prospects look healthy.

Meanwhile, Aurora Cannabis is yet to post positive adjusted EBITDA. However, its transformational business plan could deliver $60-$80 million of annualized savings by the second quarter of 2023. So, amid these savings and improved sales, the company hopes to post positive adjusted EBITDA in the first half of fiscal 2023.

Bottom line

Despite the near-term challenges, such as losing market share in the recreational segment, I believe Aurora Cannabis’s long-term growth prospects look healthy. The expanding addressable market, rising medical cannabis sales, and its accretive acquisitions could boost its financials in the coming quarters. So, I believe Aurora Cannabis would be an excellent buy for investors with over three years of investment time frame.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »